Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine

Journal of Immunology

Volumn 164, Issue 9, 2000, Pages 4797-4803

  Timmerman, John M ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARRIER PROTEINS AND BINDING PROTEINS; DRUG CARRIER; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG DESIGN; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 0034192089     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.9.4797     Document Type: Article

References (52)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Flamand, V., T. Sornasse, K. Thielemans, C. Demanet, M. Bakkus, H. Bazin, F. Tielemans, O. Leo, J. Urbain, and M. Moser. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605.
3. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
4. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
5. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
6. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
7. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255.
8. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
9. Nair, S. K., D. Boczkowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
10. Song, W., H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
11. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
12. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
13. Timmerman, J. M., and R. Levy. 1999. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:507.
14. Miller, R. A., D. G. Maloney, R. Warnke, and R. Levy. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306:517.
15. Miller, R. A., S. Hart, M. Samoszuk, C. Coulter, S. Brown, D. Czerwinski, J. Kelkenberg, I. Royston, and R. Levy. 1989. Shared idiotypes expressed by human B-cell lymphomas. N. Engl. J. Med. 321:851.
16. Campbell, M. J., W. Carroll, S. Kon, K. Thielemans, J. B. Rothbard, S. Levy, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139:2825.
17. George, A. J., A. L. Tutt, and F. K. Stevenson. 1987. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 138: 628.
18. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
19. Kwak, L. W., M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209.
20. + T cells and immunosurveillance of B-cell tumors. Proc. Natl. Acad. Sci. USA 91:5700.
21. Chakrabarti, D., and S. K. Ghosh. 1992. Induction of syngeneic cytotoxic T lymphocytes against a B cell turnor. II. Characterization of anti-idiotypic CTL lines and clones. Cell. Immunol. 144:443.
22. Cao, W., B. A. Myers-Powell, and T. J. Braciale. 1994. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes. J. Exp. Med. 179:195.
23. Abe, A., N. Emi, H. Taji, M. Kasai, A. Kohno, and H. Saito. 1996. Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy. Gene Ther. 3:988.
24. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specitic idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood 89:3129.
25. Timmerman, J. M. T. A. Davis, F. Hsu, C. Benike, T. M. Liles, D. Czerwinski, B. Taidi, A. V. Beckhoven, E. Engleman, and R. Levy. 1998. Clinical trials of dendritic cell vaccination for B cell lymphoma. J. Leukocyte Biol. 2(Suppl.):15.
26. Tao, M. H., and R. Levy. 1993. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362:755.
27. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
28. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
29. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145:1029.
30. Kwak, L. W., H. A. Young, R. W. Pennington, and S. D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93:10972.
31. + cytotoxic T lymphocyte responses. J. Immunol. 148:2357.
32. Syrengelas, A. D., and R. Levy. 1999. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol. 162: 4790.
33. Snapper, C. M., and J. J. Mond. 1993. Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 14:15.
34. Berzofsky, J. A., and I. J. Berkower. 1993. Immunogenicity and antigen structure. In Fundamental Immunology. W. E. Paul, ed. Raven Press, New York, p. 235.
35. Inaba, K., A. Granelli-Piperno, and R. M. Steinman. 1983. Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin 2-dependent mechanism. J. Exp. Med. 158:2040.
36. Inaba, K., M. D. Witmer, and R. M. Steinman. 1984. Clustering of dendritic cells, helper T lymphocytes, and histocompatible B cells during primary antibody responses in vitro. J. Exp. Med. 160:858.
37. Noelle, R. J., J. A. Ledbetter, and A. Aruffo. 1992. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol. Today 13:431.
38. Kushnir, N., L. Liu, and G. G. MacPherson. 1998. Dendritic cells and resting B cells form clusters in vitro and in vivo: T cell independence, partial LFA-1 dependence, and regulation by cross-linking surface molecules. J. Immunol. 160: 1774.
39. Francotte, M., and J. Urbain. 1985. Enhancement of antibody response by mouse dendritic cells pulsed with tobacco mosaic virus or with rabbit antiidiotypic antibodies raised against a private rabbit idiotype. Proc. Natl. Acad. Sci. USA 82: 8149.
40. Sornasse, T., V. Flamand, G. De Becker, H. Bazin, F. Tielemans, K. Thielemans, J. Urbain, O. Leo, and M. Moser. 1992. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med. 175:15.
41. Wykes, M., A. Pombo, C. Jenkins, and G. G. MacPherson. 1998. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol. 161:1313.
42. Dubois, B., B. Vanbervliet, J. Fayette, C. Massacrier, C. Van Kooten, F. Briere, J. Banchereau, and C. Caux. 1997. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J. Exp. Med. 185:941.
43. Dubois, B., C. Massacrier, B. Vanbervliet, J. Fayette, F. Briere, J. Banchereau, and C. Caux. 1998. Critical role of IL-12 in dendritic cell-induced ditferentiation of naive B lymphocytes. J. Immunol. 161:2223.
44. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J. L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189:1747.
45. 1 mice. J. Exp. Med. 140:1547.
46. Daley, M. J., H. M. Gebel, and R. G. Lynch 1978. Idiotype-specific transplantation resistance to MOPC-315: abrogation by post-immunization thymectomy. J. Immunol. 120:1620.
47. Kwak, L. W., R. Pennington, L. Boni, A. C. Ochoa, R. J. Robb, and M. C. Popescu. 1998. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J. Immunol. 160:3637.
48. King, C. A., M. B. Spellerberg, D. Zhu, J. Rice, S. S. Sahota, A. R. Thompsett, T. J. Hamblin, J. Radl, and F. K. Stevenson. 1998. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4:1281.
49. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heutler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
50. Wynn, T. A., A. Reynolds, S. James, A. W. Cheever, P. Caspar, S. Hieny. D. Jankovic, M. Strand, and A. Sher. 1996. IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J. Immunol. 157:4068.
51. Kaminski, M. S., K. Kitamura, D. G. Maloney, M. J. Campbell, and R. Levy. 1986. Importance of antibody isolype in monoclonal anti-idiotype therapy of a murine B cell lymphoma: a study of hybridoma class switch variants. J. Immunol. 136:1123.
52. Davis, T. A., D. G. Maloney, D. K. Czerwinski, T. M. Liles, and R. Levy. 1998. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92:1184.